Oligoprogression on PARP maintenance in ovarian cancer, what's the story and where do we go?

Abstract

Oligometastasis is an increasingly recognized clinical disease state, but the concept of oligoprogression is not as well studied. For patients on targeted therapies, disease progression limited to 1–3 sites may be considered amenable to treatment with local therapy allowing continuation of the targeted agent. To evaluate this concept in ovarian cancer, we investigated the proportion of patients on poly (ADP-ribose) polymerase (PARP) maintenance who developed oligoprogression and their clinical outcomes.